Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10136752 | 0.87 | MAPT (0.33) | MAPTALDH1A1NPC1LMNARAB9A | |
| SCHEMBL13509390 | 0.87 | MAPT (0.33) | MAPTALDH1A1NPC1LMNARAB9A | |
| SCHEMBL14380153 | 0.86 | TAS1R3 (0.32) | TAS1R3TAS1R1TAS1R2MAPTALDH1A1 | |
| SCHEMBL8293462 | 0.78 | P2RX7 (0.45) | MAPTALDH1A1LMNASMN1; SMN2MEN1 | |
| SCHEMBL31563093 | 0.75 | MAPT (0.50) | MAPTALDH1A1LMNASMN1; SMN2PKM | |
| SCHEMBL31563030 | 0.75 | ALDH1A1 (0.43) | MAPTALDH1A1NPC1LMNAMAPK1 | |
| SCHEMBL8300975 | 0.72 | SMN1; SMN2 (0.52) | MAPTALDH1A1NPC1LMNAMAPK1 | |
| SCHEMBL14932943 | 0.72 | HTT (0.39) | ALDH1A1NPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL8299146 | 0.72 | GRM4 (0.49) | MAPTALDH1A1NPC1LMNAALOX15 | |
| SCHEMBL4985785 | 0.72 | KMT2A (0.49) | MAPTALDH1A1NPC1MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120269769-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120034187-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8067438-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20110177030-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-21 | — | — | US | disclosed |
| US-7939667-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-20100028300-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100028300-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | US | disclosed |
| US-7642235-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| US-7642235-B2 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269769-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | TAS1R3 2060/4885TAS1R1 1930/4885TAS1R2 3053/4885 |
| US-20120034187-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | TAS1R3 2060/4885TAS1R1 1930/4885TAS1R2 3053/4885 |
| US-20100028300-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | CTRL, RPP30, RNASE1 | TAS1R3 2393/4885TAS1R1 2207/4885TAS1R2 3286/4885 |
| US-20110177030-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | TAS1R3 2060/4885TAS1R1 1930/4885TAS1R2 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.